<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1295">
  <stage>Registered</stage>
  <submitdate>15/09/2006</submitdate>
  <approvaldate>15/09/2006</approvaldate>
  <nctid>NCT00377481</nctid>
  <trial_identification>
    <studytitle>COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.</studytitle>
    <scientifictitle>A Randomised, Cross-Over Study to Investigate the Comfort of Injection of Renal Anaemia Patients Receiving Subcutaneous NeoRecormonÂ® Compared to Darbepoetin Alfa.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ML20339</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - darbepoetin alfa
Treatment: drugs - epoetin beta [NeoRecormon]

Experimental: 1 - 

Active Comparator: 2 - 


Treatment: drugs: darbepoetin alfa
30 micrograms sc weekly (2 doses)

Treatment: drugs: epoetin beta [NeoRecormon]
6000 IU sc weekly (2 doses)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Local pain due to s.c. injection (by VAS).</outcome>
      <timepoint>After each injection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient preference.</outcome>
      <timepoint>At end of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AEs, vital signs.</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients, &gt;18 years of age;

          -  patients with renal anemia or post-transplant anemia.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  poorly controlled hypertension;

          -  known hypersensitivity to NeoRecormon or darbepoetin alfa.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>48</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Gosford</hospital>
    <hospital> - Liverpool</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - St. Leonards</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Woolloongabba</hospital>
    <postcode>5011 - Adelaide</postcode>
    <postcode>2250 - Gosford</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>3168 - Melbourne</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>NSW 2148 - Sydney</postcode>
    <postcode>4102 - Woolloongabba</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin
      alfa (Aranesp) in patients with renal anemia. Eligible patients will be randomized to receive
      comparable subcutaneous injections of either darbepoetin alfa (30 micrograms) or NeoRecormon
      (6000IU). They will then be crossed over to the alternative treatment arm for further
      treatment. After each injection pain will be assessed using the visual analogue scale (VAS)
      and 6-point verbal rating scale (VRS), and patient preference will be assessed. The
      anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100
      individuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00377481</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>